anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
An oral delivery system comprising an antibody, enteric coated first minitabs, enteric coated second minitabs, and a gelatin capsule. The enteric coating on the minitabs comprise a pH-dependent enteric coating, a time-dependent enteric coating, or combination thereof. The enteric coating on the first minitabs are different from the enteric coating on the second minitabs. The antibody is within either the first, second, or both minitabs. All the minitabs are within the gelatin capsule. The oral delivery system is useful for treating Crohn's Disease, Ulcerative Colitis, or both.
The aim of this study was to compare the effect of root canal preparation techniques on the occurrence and intensity of postoperative pain in patients with asymptomatic mandibular molar teeth with periapical lesions.A hundred twenty patients who had an asymptomatic mandibular molar teeth with periapical lesion were included. For each patient, teeth were prepared with Reciproc Blue or Protaper Universal instruments. Each tooth was obturated with gutta-percha and resin-based sealer using single cone technique for mesial roots and for distal roots single cone and cold lateral compaction technique. Root canal treatment was performed in a single visit. Postoperative pain was assessed as no, mild, moderate, or severe at 6, 12, 24, 48, 72 hours and 7 days after obturation.For the comparison of pain scores between the tested instrumentation systems, the Mann Whitney test was used. Differences between postoperative pain intencity for each instrumentation technique, at different time intervals, were assessed by the Friedman test. For the association of pain and an analgesic intake with gender, the chi-square test was performed. For the association of pain with age and an analgesic intake were calculated using Mann Whitney test. A P value \< .05 or less was considered significant.
Patient in this study group will get 30 minutes session, twice weekly for 6 weeks. Neural mobilization technique will be applied to the subjects in addition to conventional treatment.
The combined immunization group is randomly divided into two subgroups, 120 subjects in each group. The combined immunization subgroup Ⅰ receive SARS-CoV-2 inactivated vaccine (Vero cell)\&Quadrivalent Influenza Vaccine on day0 and SARS-CoV-2 inactivated vaccine (Vero cell) (second dose) on day 28.The combined immunization subgroup Ⅱ receive SARS-CoV-2 inactivated vaccine (Vero cell) on day 0 and SARS-CoV-2 inactivated vaccine (Vero cell) (second dose) \& Quadrivalent Influenza Vaccine on day 28.
Macromolecular reconstituted collagen is prepared by treating natural insoluble collagen with an aqueous solution comprised of an alkali sulfate salt and an alkali metal hydroxide for at least 48 hours to saponify fats suspended within the natural insoluble collagen. The fat free collagen is then treated with an aqueous solution comprised of an alkali metal sulfate for at least four hours to stabilize the interfibular bonds between individual polypeptide chains. The collagen is then dissolved in an aqueous acid solution and frozen at a rate of -20 DEG C./hour. The frozen collagen is vacuum dried at 10-3 to 10-5 torr for at least 16 hours to produce a biologically active collagen article. Various biologically active materials may be added to the aqueous acid solution prior to freezing. The collagen product may then be implanted into an animal or the like and the medication slowly released. The article can remain within the biological system and it will slowly dissolve due to enzymatic digestion and through other biological processes.
The patient should be instructed to:

  1. Use oxiconazole nitrate cream as directed by the physician. The hands should be washed after applying the medication to the affected area(s). Avoid contact with the eyes, nose, mouth, and other mucous membranes. Oxiconazole nitrate cream is for external use only.
  2. Use the medication for the full treatment time recommended by the physician, even though symptoms may have improved. Notify the physician if there is no improvement after 2 to 4 weeks, or sooner if the condition worsens (see below).
  3. Inform the physician if the area of application shows signs of increased irritation, itching, burning, blistering, swelling, or oozing.
  4. Avoid the use of occlusive dressings unless otherwise directed by the physician.
  5. Do not use this medication for any disorder other than that for which it was prescribed.
FIELD: organic chemistry, biochemistry, medicine, pharmacy. SUBSTANCE: invention proposes compounds of the formula (I):   or their pharmaceutically acceptable salts wherein X represents phenyl ring substituted with halogen atom or dimethylamino-group; Z represents -NH-; each among R 1 ,R 3 ,R 4  represents hydrogen atom; R 2  is taken among different unsaturated acyl groups enumerated in claim 1 under condition that when R 2  is taken among the group consisting of:   or   then R 5  represents independently and solely hydrogen atom, alkyl comprising 1-6 carbon atoms or carboxy-group; X doesn't represent phenyl ring substituted solely with one or some halogen atoms. Compounds are inhibitors of tyrosine kinase and can be used for treatment of cancer and some renal diseases, such as polycystic renal disease. Invention relates also to method for inhibition of biological effect of protein tyrosine kinase with damaged regulation in mammal, treatment or inhibition of tumors growth in mammal, to pharmaceutical composition inhibiting activity of receptor protein tyrosine kinase, epidermal growth factor of cells and to method for preparing compound of the formula (I). EFFECT: valuable medicinal properties of compounds. 20 cl, 5 tbl, 82 ex
Group B will receive an L400 Compete Orthotic (https://www.aetrex.com/search?q=l420\&search-button=\&lang=en_US) alone. The investigators will send an instruction sheet along with the Orthotic in the post, explaining how to use it. Alternatively, an online video tutorial on how to use the Orthotic will also be available throughout the study. The group will be asked to continue with usual activities, using the Orthotic wherever possible.
A liniment is disclosed for use in conjunction with massage or other topical application method, and is adapted for any application as a part of a medically recommended treatment, particularly where pain management is involved. The liniment for topical application includes a mixture of ethyl alcohol, methyl hydrate and distilled water. To this solution is added horse-radish and powdered cayenne pepper. The mixture is sealed for 21 days, with twice daily mixing. Particulate matter formed in the mix is separated out, leaving the liniment for use. The liniment may be applied topically to the skin in areas of pain and discomfort.
Patients with solid tumor will receive intravenous infusions of EMB-07 weekly (QW). Dose escalation will continue until the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D) is reached or all planned doses are administered.
Cyclooxygenase (COX) enzymes are pivotal in inflammation and cancer development. COX-2, in particular, has been implicated in tumor growth, angiogenesis, and immune evasion. Recently, COX-2 inhibitors have arisen as potential therapeutic agents in cancer treatment. In addition, combining COX inhibitors with other treatment modalities has demonstrated the potential to improve therapeutic efficacy. This review aims to investigate the effects of COX inhibition, both alone and in combination with other methods, on signaling pathways and carcinogenesis in various cancers. In this study, a literature search of all major academic databases was conducted (PubMed, Scholar google), including the leading research on the mechanisms of COX-2, COX-2 inhibitors, monotherapy with COX-2 inhibitors, and combining COX-2-inhibitors with chemotherapeutic agents in tumors. The study encompasses preclinical and clinical evidence, highlighting the positive findings and the potential implications for clinical practice. According to preclinical studies, multiple signaling pathways implicated in tumor cell proliferation, survival, invasion, and metastasis can be suppressed by inhibiting COX. In addition, combining COX inhibitors with chemotherapy drugs, targeted therapies, immunotherapies, and miRNA-based approaches has enhanced anti-tumor activity. These results suggest that combination therapy has the potential to overcome resistance mechanisms and improve treatment outcomes. However, caution must be exercised when selecting and administering combination regimens. Not all combinations of COX-2 inhibitors with other drugs result in synergistic effects; some may even have unfavorable interactions. Therefore, personalized approaches that consider the specific characteristics of the cancer and the medications involved are crucial for optimizing therapeutic strategies. In conclusion, as monotherapy or combined with other methods, COX inhibition bears promise in modulating signaling pathways and inhibiting carcinogenesis in various cancers. Additional studies and well-designed clinical trials are required to completely elucidate the efficacy of COX inhibition and combination therapy in enhancing cancer treatment outcomes. This narrative review study provides a detailed summary of COX-2 monotherapy and combination targeted therapy in cancer treatment.
The invention discloses a dynamic cycle extraction method for plant extracts. The method disclosed by the invention is characterized in that plant raw materials are subjected to dynamic cycle extraction for multiple times by adopting an extraction solvent in the extraction course; the extraction solvent for each time is 1.5-3 times of the mass of the raw materials; the cycle count of the solvent is 2-5; and the total extraction time is 2-5. Compared with the conventional percolation extraction process, the method disclosed by the invention has the advantages that the extraction speed is enhanced; the unit concentration of extraction ingredients is enhanced; the temperature adaptability of the extraction solvent is wide; the process is simple and easy to carry out and the like. Compared with a conventional dynamic countercurrent extraction process, the method disclosed by the invention has the advantages that the utilization rate of unit extraction equipment is improved; the equipment adaptability is wide; the process is easy and easy to carry out and the like. The method disclosed by the invention can be used for producing plant extracts, and is particularly suitable for extracting effective ingredients of plants, which have high thermal sensitivity, high deterioration possibility and other similar properties. The invention simultaneously discloses application of the dynamic cycle extraction process in preparing two plant extracts of Polygonum cuspidatum and radix salviae miltiorrhizae.
Patients undergo clinical observation until documented first progression. After progression, patients receive 177Lu-PSMA-617 IV over 10-15 minutes on day 1 of each cycle. Cycles repeat every 42 days for 6 cycles in the absence of disease progression or unacceptable toxicity. Patients receive gallium Ga 68-labeled PSMA-11 IV and undergo PET/CT and a bone scan during screening and on the trial. Patients also undergo SPECT/CT and blood sample collection on the trial.
The Oxygen Reserve Index (ORI) is a new development in multiple wavelength pulse oximetry, reflecting the arterial partial oxygen pressure (PaO2) continuously and non-invasively by an index. In contrast to established standard oxygen saturation (SpO2) measurements, ORI detects a drop of PaO2 until the threshold of 100 mmHg. During anaesthesia induction-associated apnoeic periods ORI may detect a drop of PaO2 early enough for the anaesthesiologist to interrupt the intubation procedure and re-start oxygenation. In contrast, due to the flat upper part of the oxyhaemoglobin dissociation curve, SpO2 stays at values above 90% until PaO2 falls below 60mmHg. At this point, SpO2 drops rapidly and a pro- longed hypoxic dip is the consequence. To avoid this potentially harmful hypoxic dip, continuous monitoring of PaO2 using ORI would be advantageous during anaesthesia induction phase.

This clinical study aims to evaluate the time benefit between alarm of hypoxaemia by the ORI-monitoring and the start of the dropping of oxygen saturation. Pre-set and pre-described ORI-alarms will be checked for their utility and a new ORI-alarm will be defined that is potentially more useful. As secondary endpoints the study examines the correlation of ORI with PO2, the influence of patient or measurement characteristics on the correlation of ORI with PO2 and the influence of the measurement site on ORI-measurement.
Although various joint injuries result in post-traumatic osteoarthritis (PTOA), differences in chondrocyte response to specific injuries, such as blunt compression or fracture, are unclear. Furthermore, the role of underlying joint inflammation, or synovitis, is often not considered. We investigated how injury mechanisms and underlying synovitis affect chondrocyte gene expression using osteochondral injury models with synovial co-culture. We hypothesized that the state of synovitis as well as the mechanism of biomechanical cartilage injury differentially alter the gene expression of chondrocytes and that these responses are regulated by the pro-inflammatory cytokine interleukin 1 (IL-1). The mechanism of injury and level of synovial inflammation both significantly regulated chondrocyte gene expression and associated pathways, uncovering distinct characteristics of fracture and compression injury mechanisms. Targeting IL-1 following injury reduced the inflammatory response and could have clinical implications. The results from this study show that crosstalk between biomechanics and inflammation in the context of synovitis and cartilage injury mechanism is an important consideration for PTOA.
A capsule for oral delivery of a composition comprises 60 % to 95 % by weight of gum arabic and to the remainder a water-soluble polymer, a hydrocolloid and a plasticizer. The proportion of gum arabic is preferably 70 % to 90% by weight of all components. The water-soluble polymer is preferably a hydroxypropylmethylcellulose or carboxymethylcellulose or alginetes. The hydrocolloid is preferably a carrageenan or agar gum or galactomannan or a mixture thereof. The capsule may be is containing medicinal or pharmaceutical agents as fill material. The capsule has good mechanical strength and low brittleness. The presence of gum arabic in a solution raises the solubility of other film-forming polymers.
PURPOSE:To produce slow releasing microcapsules by mixing proper amts. of plural kinds of microcapsules having stepwise different releasing speeds of the core substance (chemicals) so that a fixed quantity of the core substance is released with the lapse of time. CONSTITUTION:Plural kinds of microcapsules are produced by stepwise changing the ratio of a core substance to a wall substance and proper amts. of the microcapsules are mixed so that a fixed quantity of the core substance is released with the lapse of time. The releasing speed of the core substance can be regulated by changing a factor such as the thickness of the walls of microcapsules or the diameter of micropores in the walls, preferably the thickness of the walls. The resulting microcapsules are slow releasing microcapsules for releasing a nearly fixed quantity of chemicals with the lapse of time, can effectively utilize chemicals such as pharmaceuticals or agricultural chemicals and can enhance remedial value.
The human microbiome (i.e., the collection of microbial genes found in and on the human body) has been observed to be associated with numerous health conditions, but current methodological studies suggest that collection method, laboratory handling, bioinformatic processing of the data, and other factors can greatly affect microbiome study findings. In cohort studies, samples are typically collected at baseline, but are often not processed until sufficient cases have accumulated. This type of study design will require that samples remain frozen for likely many years prior to laboratory handling for microbiome measurements. To our knowledge, no study has considered the impact of long term storage of oral samples on oral microbiome characteristics. Therefore, we will evaluate the effect of long term storage of two oral sample collection methods (OMNIgene ORAL and Scope mouthwash) from 30 individuals who work at the NCI on oral microbiome characteristics. We will request that each participant will provide samples on 6 separate days over the course of two weeks. Participants will also fill out a short questionnaire. We will create aliquots from the pooled OMNIgene ORAL and Scope mouthwash samples from each individual, and immediately extract the DNA one aliquot. The remaining aliquots will be frozen at -80 degrees C and DNA will be extracted after one month, three months, six months, and one year after collection. The remaining aliquots will remain in the -80 degress C freezer for even longer term testing and other future studies. We will compare the microbial profiles from the stored samples to the immediately extracted samples to determine the effect of storage on oral samples.
Coordination between the legs during walking is often disrupted after neurological injury, resulting in asymmetric gait patterns. Recent data shows that walking patterns can be altered through treadmill training, even after central nervous system damage. The investigators have studied short-term adaptation of inter-limb coordination during walking using a split-belt treadmill to control speed of the two legs independently. Our findings demonstrate that walking patterns are adaptable, and that this process is dependent on cerebellar integrity. The investigators have also shown that people with cerebral damage from stroke can benefit in the short-term to correct asymmetric walking patterns. Since all of our previous work has focused on single training sessions, the investigators would like to study long-term effects of split belt treadmill training. Therefore, the purpose of this study is to prepare for a clinical trial of split-belt treadmill training to treat walking pattern deficits from cerebral damage. The investigators will gather data to determine whether different schedules and types of long-term training on a custom split-belt treadmill are likely to change/improve walking symmetry.

The investigators will study subjects with and without cerebral damage. Subjects without hemiparesis will simply be trained daily for 2 weeks to understand how they learn a new pattern on the treadmill for comparison with patients. Subjects with hemiparesis will undergo training daily for 2 weeks or the same dose of training, spread over 4 weeks. Training for the subjects with hemiparesis will either be conventional treadmill walking or split-belt treadmill walking with one leg moving faster than the other. The investigators will study children and adults with hemiparesis. These studies will provide important new information about normal mechanisms of locomotor adaptation, as well as providing a new rehabilitation tool for people with asymmetric gait patterns. Note that this study is not an aerobic conditioning program since subjects will work well below their age-adjusted target heart rate; it is instead a retraining program aimed at teaching people a new inter-limb coordination pattern. This study is also critical for developing procedural reliability processes, calculating effect sizes, training clinical staff, and determining other salient clinical variables in preparation for a randomized clinical trial.
Suicidality and Antidepressant Drugs

Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders. Anyone considering the use of desipramine hydrochloride or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need. Short-term studies did not show an increase in the risk of suicidality with antidepressants compared to placebo in adults beyond age 24; there was a reduction in risk with antidepressants compared to placebo in adults aged 65 and older. Depression and certain other psychiatric disorders are themselves associated with increases in the risk of suicide. Patients of all ages who are started on antidepressant therapy should be monitored appropriately and observed closely for clinical worsening, suicidality, or unusual changes in behavior. Families and caregivers should be advised of the need for close observation and communication with the prescriber. Desipramine hydrochloride is not approved for use in pediatric patients. (See WARNINGS: Clinical Worsening and Suicide Risk, PRECAUTIONS: Information for patients and PRECAUTIONS: Pediatric use

DESCRIPTION:

Desipramine hydrochloride USP is an antidepressant drug of the tricyclic type, and is chemically: 5H-Dibenz[b,f ]azepine-5-propanamine,10,11-dihydro-N-methyl-,monohydrochloride.

Inactive Ingredients: The following inactive ingredients are contained in all strengths: croscarmellose sodium, hypromellose, anhydrous lactose, magnesium stearate, povidone, sodium lauryl sulfate, titanium dioxide and trace amounts of other ingredients. The 25 mg, 50 mg, 75 mg, and 100 mg tablets also contain FD&C Blue No. 1 Aluminum Lake.
Recently, emerging evidence has suggested that obesity become a prevalent health threat worldwide. Reportedly, CTRP9 can ameliorate HFD induced obesity. However, the molecular mechanism underlying the role of CTRP9 in obesity remains elusive. In this study, we reported its major function in the regulation of lipolysis. First, we found that the expression of CTRP9 was decreased in mature adipocytes and white adipose tissue of obese mice. Then, we showed that overexpression adipose tissue CTRP9 alleviated diet-induced obesity and adipocytes hypertrophy, improved glucose intolerance and raised energy expenditure. Moreover, CTRP9 increased the lipolysis in vitro and vivo. Additionally, we determined that CTRP9 enhanced autophagy flux in adipocytes. Intriguingly, knock down Beclin1 by SiRNA abolished the effect of CTRP9 on lipolysis. Mechanically, CTRP9 enhanced the expression of SNX26. We demonstrated that SNX26 was a component of the ATG14L-Beclin1-VPS34 complex and enhanced the assembly of the autophagy-initiation complex. Collectively, our results suggested that CTRP9 alleviated diet induced obesity through enhancing lipolysis mediated by autophagy-initiation complex formation.